Editorial: stratifying risk of adverse outcomes in cirrhosis—the Hepquant SHUNT test. Authors' reply

20211 citationseditorialbronze Open Access

Authors

Sumeet K. Asrani · Baylor University Medical Center

Gregory T. Everson · Colorado Humanities

Abstract

LINKED CONTENT This article is linked to Fallahzadeh et al and Maan & Sonneveld papers. To view these articles, visit https://doi.org/10.1111/apt.16283 and https://doi.org/10.1111/apt.16299

Topics & Keywords

Liver Disease and Transplantation Liver Disease Diagnosis and Treatment Hepatocellular Carcinoma Treatment and Prognosis

Publication Details

Published in: Alimentary Pharmacology & Therapeutics

Volume 53, Issue 8, pp. 941-942

DOI: 10.1111/apt.16311

Field-Weighted Citation Impact: 0.12

Command Palette

Editorial: stratifying risk of adverse outcomes in cirrhosis—the Hepquant SHUNT test. Authors' reply

Authors

Abstract

Topics & Keywords

Publication Details